Central nervous system cavernous hemangioma

BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

Retrieved on: 
Monday, December 16, 2019
Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma, Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma

The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.

Key Points: 
  • The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.
  • Data from a recent clinical study indicates that BA-1049 has promise as a therapeutic agent for the treatment of cavernous angioma (CA), also called cerebral cavernous malformation (CCM).
  • CA is a serious genetic disease with no current treatment available other than surgical removal of the brain lesions.
  • We are very pleased with this expansion of our patent estate for BA-1049, said Lisa McKerracher, PhD, CEO, BioAxone BioSciences.

BioAxone BioSciences Announces Publication in Translational Stroke Research of Cavernous Angioma Disease Research Article

Retrieved on: 
Thursday, September 12, 2019
Biotechnology, Health, Genetics, Pharmaceutical, Benign neoplasms, Organ systems, Epidemiology, Medicine, Cavernous hemangioma, Angioma, Stroke, Brain damage, Central nervous system cavernous hemangioma, Draft:Cerebral Cavernous Malformation

CA is a rare genetic disease with no current treatment available other than surgical removal of the brain lesions.

Key Points: 
  • CA is a rare genetic disease with no current treatment available other than surgical removal of the brain lesions.
  • CA (also called cerebral cavernous malformation (CCM) is a serious genetic disease.
  • In angioma, endothelial cells form single or multiple cystic brain lesions that leak and may cause seizure, hemorrhagic stroke and neurological deficits.
  • Leveraging 20 years of pioneering research in axon regeneration and diseases involving Rho/ROCK signaling, BioAxones lead drug candidate is an orally-available ROCK2 inhibitor restoring endothelial cell barriers in cavernous angioma (CA) and stroke.

Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation

Retrieved on: 
Tuesday, July 10, 2018
Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, Angioma, Clinical medicine, Central nervous system cavernous hemangioma, CCM2

Later this year, Recursion plans to initiate the company's first clinical trial to evaluate the safety and pharmacokinetics of REC-994 as an oral treatment for CCM.

Key Points: 
  • Later this year, Recursion plans to initiate the company's first clinical trial to evaluate the safety and pharmacokinetics of REC-994 as an oral treatment for CCM.
  • Cerebral cavernous malformations (CCMs) are collections of small blood vessels in the brain that are enlarged and irregular in structure which lead to altered blood flow.
  • "A non-surgical treatment for cerebral cavernous malformation could have a significant impact on patients' lives," said Angioma Alliance President Dr. Connie Lee.
  • "We are excited about this important milestone and our continued work with Recursion to advance a novel oral treatment into clinical trials."